Compile Data Set for Download or QSAR
Report error Found 358 Enz. Inhib. hit(s) with all data for entry = 690
TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287156(US9567339, Example A.1.7)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287157(US9567339, Example A.1.8)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287159(US9567339, Example A.1.10)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287160(US9567339, Example A.1.11)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287161(US9567339, Example A.1.12)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287162(US9567339, Example A.1.13)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287163(US9567339, Example A.1.14)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287151(US9567339, Example A.1.2)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287153(US9567339, Example A.1.4)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287154(US9567339, Example A.1.5)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287155(US9567339, Example A.1.6)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287172(US9567339, Example A.1.23)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287173(US9567339, Example A.1.24)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287174(US9567339, Example A.1.25)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287175(US9567339, Example A.1.26)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287176(US9567339, Example A.1.27)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287178(US9567339, Example A.1.29)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287179(US9567339, Example A.1.30)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287164(US9567339, Example A.1.15)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287165(US9567339, Example A.1.16)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287166(US9567339, Example A.1.17)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287167(US9567339, Example A.1.18)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287168(US9567339, Example A.1.19)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287169(US9567339, Example A.1.20)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287170(US9567339, Example A.1.21)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287171(US9567339, Example A.1.22)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287188(US9567339, Example A.1.39)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287189(US9567339, Example A.1.40)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287190(US9567339, Example A.1.41)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287191(US9567339, Example A.1.42)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287192(US9567339, Example A.1.43)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287193(US9567339, Example A.1.44)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287194(US9567339, Example A.1.45)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287195(US9567339, Example A.2.1)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287180(US9567339, Example A.1.31)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287181(US9567339, Example A.1.32)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287182(US9567339, Example A.1.33)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287184(US9567339, Example A.1.35)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287185(US9567339, Example A.1.36)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287186(US9567339, Example A.1.37)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287187(US9567339, Example A.1.38)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287204(US9567339, Example A.3.8)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287205(US9567339, Example A.4.1)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287206(US9567339, Example A.4.2)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287207(US9567339, Example A.4.3)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287208(US9567339, Example A.4.4)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287209(US9567339, Example A.4.5)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287210(US9567339, Example A.4.6)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287211(US9567339, Example A.4.7)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [393-659](Human)
Abbvie

US Patent
LigandPNGBDBM287196(US9567339, Example A.2.2)
Affinity DataIC50: 100nMpH: 6.5 T: 2°CAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

Displayed 1 to 50 (of 358 total ) | Next | Last >>
Jump to: